Pharvaris (NASDAQ: PHVS) has recently been upgraded by Wall Street Zen from a “sell” rating to a “hold” rating, reflecting a positive shift in investor sentiment...
On August 16, 2023, Citizens Jmp began coverage of Assembly Biosciences (NASDAQ: ASMB), assigning an “outperform” rating along with a target price of $38.00. This biopharmaceutical...
Assembly Biosciences (NASDAQ: ASMB) received a significant boost as Guggenheim raised its price target for the biopharmaceutical company’s stock from $31.00 to $39.00. This adjustment, reported...
